Show simple item record

dc.creatorCummins Jr., Joseph M.
dc.date.accessioned2019-06-17T17:09:48Z
dc.date.available2019-06-17T17:09:48Z
dc.date.issued1991-05-28
dc.identifier.urihttp://hdl.handle.net/1969.1/177108
dc.description.abstractNeoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of about 0.1 to about 5 IU/lb per day by contacting said interferon with oral/pharyngeal mucosa. Interferon is administered in solution or in a novel solid unitary dosage form adapted to be dissolved in saliva when placed in the mouth.en
dc.languageeng
dc.publisherUnited States. Patent and Trademark Office
dc.rightsPublic Domain (No copyright - United States)en
dc.rights.urihttp://rightsstatements.org/vocab/NoC-US/1.0/
dc.titleTreatment of immuno-resistant disease with low-dose interferonen
dc.typeUtility patenten
dc.format.digitalOriginreformatted digitalen
dc.description.countryUS
dc.contributor.assigneeThe Texas A&M University System
dc.identifier.patentapplicationnumber07/465527
dc.subject.uspcprimary424/85.4
dc.subject.uspcother424/85.6
dc.subject.uspcother424/85.7
dc.date.filed1990-01-17
dc.publisher.digitalTexas A&M University. Libraries


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record